Poxel Stock price

Equities

POXEL

FR0012432516

Biotechnology & Medical Research

Market Closed - Euronext Paris 12:35:06 2024-03-28 pm EDT 5-day change 1st Jan Change
0.518 EUR +5.50% Intraday chart for Poxel +0.19% -5.99%
Sales 2023 * 1.6M 1.72M Sales 2024 * 56.8M 61.21M Capitalization 20.07M 21.63M
Net income 2023 * -25M -26.94M Net income 2024 * 26M 28.02M EV / Sales 2023 * 52.5 x
Net Debt 2023 * 64M 68.97M Net Debt 2024 * 52.8M 56.9M EV / Sales 2024 * 1.28 x
P/E ratio 2023 *
-0.58 x
P/E ratio 2024 *
0.56 x
Employees 15
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.57%
More Fundamentals * Assessed data
Dynamic Chart
1 day+5.50%
1 week+0.19%
Current month+18.81%
1 month+18.81%
3 months-14.38%
6 months+43.89%
Current year-5.99%
More quotes
1 week
0.48
Extreme 0.477
0.53
1 month
0.41
Extreme 0.4135
0.57
Current year
0.36
Extreme 0.364
0.62
1 year
0.30
Extreme 0.297
0.95
3 years
0.30
Extreme 0.297
7.75
5 years
0.30
Extreme 0.297
13.80
10 years
0.30
Extreme 0.297
17.74
More quotes
Managers TitleAgeSince
Founder 61 09-03-05
Founder - 09-03-05
Founder - 09-03-05
Members of the board TitleAgeSince
Director/Board Member 68 15-03-11
Director/Board Member 57 15-03-04
Founder 50 09-03-05
More insiders
Date Price Change Volume
24-03-28 0.518 +5.50% 214,651
24-03-27 0.491 -1.80% 84,835
24-03-26 0.5 -4.21% 190,670
24-03-25 0.522 +0.38% 27,431
24-03-22 0.52 +0.58% 102,137

Real-time Euronext Paris, March 28, 2024 at 12:35 pm EDT

More quotes
Poxel is a biopharmaceutical company specializing in developing innovative treatments for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and rare diseases. TWYMEEG® (Imeglimine), Poxel's lead product and the first in its class of medicines, which targets mitochondrial dysfunction, has been marketed in Japan for the treatment of type 2 diabetes. For the treatment of NASH, the PXL065 met its primary endpoint in a streamlined Phase II trial, and PXL770 has completed a Phase IIa proof-of-concept study by reaching its objectives. In adrenoleukodystrophy (ALD), a rare inherited metabolic disease, the company intends to initiate Phase IIa proof-of-concept studies with the PXL065 and the PXL770 in patients with adrenomyeloneuropathy (AMN).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.518 EUR
Average target price
3.5 EUR
Spread / Average Target
+575.68%
Consensus
  1. Stock
  2. Equities
  3. Stock Poxel - Euronext Paris